Committee for Medicinal Products for Human Use (CHMP) has recommended approving AstraZeneca’s Fasenra (benralizumab) to treat ...

Since GSK’s Nucala and AstraZeneca’s Fasenra were approved two years apart to treat patients with severe asthma, the IL-5 ...

Opens in a new tab or window A safety update for abrocitinib has shown the drug to be safe out to nearly 4 years for the treatment of moderate-to-severe atopic dermatitis (AD). The risk of adverse ...

The best ad blockers are unfortunately very necessary to survive on the modern internet. It doesn't matter which sites you browse, there's the risk of being harassed by pop-ups, tracker cookies ...

In a consensus survey study, participants with atopic dermatitis (AD) agreed on a patient-centered definition of AD flare, which most agreed would help when communicating with their healthcare ...

Accidental death and dismemberment (AD&D) insurance is insurance—usually added as a rider to a health or life insurance policy—that covers the unintentional death or dismemberment of the insured.

First, YouTube subjected viewers to longer unskippable ads. Now, not even pausing your screen will let users escape. The Google-owned platform confirmed Thursday that it has “widely rolled out ...

Scams originating from fake ads on social media have increased dramatically. Here's what to know and how to protect yourself. The majority of people who fall for fake ads on social media don’t ...

Adbry is currently indicated in the U.S. for patients 12 years and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription ...

Approximately two-thirds of individuals with an empirical diagnosis of eczema or AD had moderate to severe symptoms, one-third had sleep disturbances, and one-quarter had chronic unremitting symptoms.

She's worked on ad campaigns for many trusted brands such as Nike, Subaru, Polaris, Red Bull and Progressive Insurance, just to name a few. Beyond her profes... Editorial Note: We earn a ...